Literature DB >> 17211455

Neuromedin U can exert colon-specific, enteric nerve-mediated prokinetic activity, via a pathway involving NMU1 receptor activation.

N B Dass1, A K Bassil, V J North-Laidler, R Morrow, E Aziz, B R Tuladhar, G J Sanger.   

Abstract

BACKGROUND AND
PURPOSE: The neuromedin U (NMU) receptors, NMU1 and NMU2, are expressed in the gut but their functions are unclear. This study explores the role of NMU in gastrointestinal motility. EXPERIMENTAL APPROACH: The effects of NMU were examined in the forestomach and colon isolated from NMU2R wild-type and NMU2R-/- (knockout) mice, looking for changes in muscle tension and in nerve-mediated responses evoked by electrical field stimulation (EFS), and in models of peristalsis in mouse colon and faecal pellet transit in guinea-pig colon. KEY
RESULTS: In the mouse forestomach, NMU (1 nM-10 microM) concentration-dependently induced muscle contraction, in the presence of tetrodotoxin and atropine, in preparations from both wild-type and NMU2R-/- mice (pEC50: 7.9, 7.6, Emax: 0.26, 0.20g tension, respectively, n=8 each concentration). The same concentrations of NMU had no consistent effects on the responses to EFS (n=8). In the mouse colon, NMU (0.1 nM-1 microM) had no significant effect on baseline muscle tension (n=8), but concentration-dependently potentiated EFS-evoked contractions in preparations from both wild-type and NMU2R-/- mice, pEC50: 8.1, 7.8, Emax: 24%, 21%, respectively, n=6-11. NMU (0.01 nM-0.1 microM, n=5-7) concentration-dependently decreased the interval between waves of peristalsis in the mouse colon (pEC50: 8.8) and increased the rate at which a faecal pellet moved along the guinea-pig colon. CONCLUSIONS AND IMPLICATIONS: These results demonstrate that NMU exerts colon-specific, nerve-mediated, prokinetic activity, via a pathway involving activation of NMU1 receptors. This suggests that this receptor may represent a molecular target for the treatment of intestinal motility disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17211455      PMCID: PMC2189728          DOI: 10.1038/sj.bjp.0707004

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

1.  Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system.

Authors:  R Raddatz; A E Wilson; R Artymyshyn; J A Bonini; B Borowsky; L W Boteju; S Zhou; E V Kouranova; R Nagorny; M S Guevarra; M Dai; G S Lerman; P J Vaysse; T A Branchek; C Gerald; C Forray; N Adham
Journal:  J Biol Chem       Date:  2000-10-20       Impact factor: 5.157

2.  Identification of a human gastrointestinal tract and immune system receptor for the peptide neuromedin U.

Authors:  J A Hedrick; K Morse; L Shan; X Qiao; L Pang; S Wang; T Laz; E L Gustafson; M Bayne; F J Monsma
Journal:  Mol Pharmacol       Date:  2000-10       Impact factor: 4.436

3.  Neuromedin U-8 and U-25: novel uterus stimulating and hypertensive peptides identified in porcine spinal cord.

Authors:  N Minamino; K Kangawa; H Matsuo
Journal:  Biochem Biophys Res Commun       Date:  1985-08-15       Impact factor: 3.575

4.  Identification of receptors for neuromedin U and its role in feeding.

Authors:  A D Howard; R Wang; S S Pong; T N Mellin; A Strack; X M Guan; Z Zeng; D L Williams; S D Feighner; C N Nunes; B Murphy; J N Stair; H Yu; Q Jiang; M K Clements; C P Tan; K K McKee; D L Hreniuk; T P McDonald; K R Lynch; J F Evans; C P Austin; C T Caskey; L H Van der Ploeg; Q Liu
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

5.  Neuromedin U is a potent agonist at the orphan G protein-coupled receptor FM3.

Authors:  P G Szekeres; A I Muir; L D Spinage; J E Miller; S I Butler; A Smith; G I Rennie; P R Murdock; L R Fitzgerald; H l Wu; L J McMillan; S Guerrera; L Vawter; N A Elshourbagy; J L Mooney; D J Bergsma; S Wilson; J K Chambers
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

6.  Identification and functional characterization of a novel subtype of neuromedin U receptor.

Authors:  M Hosoya; T Moriya; Y Kawamata; S Ohkubo; R Fujii; H Matsui; Y Shintani; S Fukusumi; Y Habata; S Hinuma; H Onda; O Nishimura; M Fujino
Journal:  J Biol Chem       Date:  2000-09-22       Impact factor: 5.157

7.  Identification of a novel neuromedin U receptor subtype expressed in the central nervous system.

Authors:  L Shan; X Qiao; J H Crona; J Behan; S Wang; T Laz; M Bayne; E L Gustafson; F J Monsma; J A Hedrick
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

8.  Characterization of neuromedin U effects in canine smooth muscle.

Authors:  Timothy D Westfall; Gerald P McCafferty; Mark Pullen; Susan Gruver; Anthony C Sulpizio; V Nambi Aiyar; Jyoti Disa; Lisa C Contino; Ishrat J Mannan; J Paul Hieble
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

9.  Characterization of neuromedin U like immunoreactivity in rat, porcine, guinea-pig and human tissue extracts using a specific radioimmunoassay.

Authors:  J Domin; M A Ghatei; P Chohan; S R Bloom
Journal:  Biochem Biophys Res Commun       Date:  1986-11-14       Impact factor: 3.575

10.  Species-dependent smooth muscle contraction to Neuromedin U and determination of the receptor subtypes mediating contraction using NMU1 receptor knockout mice.

Authors:  Clodagh E Prendergast; Magda F Morton; Katherine W Figueroa; Xiaodong Wu; Nigel P Shankley
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

View more
  3 in total

Review 1.  Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S.

Authors:  J D Mitchell; J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  2009-06-10       Impact factor: 8.739

2.  Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice.

Authors:  Hiroaki Nagai; Tomoko Kaisho; Kotaro Yokoyama; Tomoko Asakawa; Hisashi Fujita; Kouta Matsumiya; Jiro Noguchi; Kazue Tsuchimori; Naoki Nishizawa; Yoko Kanematsu-Yamaki; Katsuko Dote; Hiroshi Inooka; Jun-Ichi Sakamoto; Tetsuya Ohtaki; Taiji Asami; Shiro Takekawa
Journal:  Br J Pharmacol       Date:  2017-12-18       Impact factor: 8.739

3.  Defining the transcriptomic landscape of the developing enteric nervous system and its cellular environment.

Authors:  Sweta Roy-Carson; Kevin Natukunda; Hsien-Chao Chou; Narinder Pal; Caitlin Farris; Stephan Q Schneider; Julie A Kuhlman
Journal:  BMC Genomics       Date:  2017-04-12       Impact factor: 3.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.